RJA
EBS icon

Raymond James & Associates’s Emergent Biosolutions EBS Stock Holding History

Raymond James & Associates’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21,538
Closed -$669K – 3995
2022
Q2 		$669K Buy
21,538
+329
+2% +$11.2K ﹤0.01% 2723
2022
Q1 		$871K Buy
21,209
+4,258
+25% +$188K ﹤0.01% 2699
2021
Q4 		$737K Sell
16,951
-2,036
-11% -$92.1K ﹤0.01% 2821
2021
Q3 		$951K Buy
18,987
+1,331
+8% +$80.6K ﹤0.01% 2616
2021
Q2 		$1.11M Sell
17,656
-13,641
-44% -$876K ﹤0.01% 2516
2021
Q1 		$2.91M Buy
31,297
+11,081
+55% +$1.13M ﹤0.01% 1777
2020
Q4 		$1.81M Buy
20,216
+980
+5% +$89.9K ﹤0.01% 1945
2020
Q3 		$1.99M Buy
19,236
+2,247
+13% +$242K ﹤0.01% 1776
2020
Q2 		$1.34M Buy
16,989
+4,654
+38% +$347K ﹤0.01% 1962
2020
Q1 		$714K Buy
+12,335
New +$711K ﹤0.01% 2192
2019
Q4 		– Sell
-4,718
Closed -$247K – 3682
2019
Q3 		$247K Buy
+4,718
New +$220K ﹤0.01% 3126
2019
Q2 		– Sell
-9,081
Closed -$459K – 3672
2019
Q1 		$459K Sell
9,081
-2,074
-19% -$122K ﹤0.01% 2715
2018
Q4 		$661K Buy
11,155
+416
+4% +$26.8K ﹤0.01% 2351
2018
Q3 		$707K Buy
10,739
+317
+3% +$18.5K ﹤0.01% 2466
2018
Q2 		$526K Sell
10,422
-374
-3% -$19.5K ﹤0.01% 2647
2018
Q1 		$568K Buy
10,796
+3,136
+41% +$156K ﹤0.01% 2484
2017
Q4 		$356K Hold
7,660
– – ﹤0.01% 2741
2017
Q3 		$310K Sell
7,660
-414
-5% -$15K ﹤0.01% 2771
2017
Q2 		$274K Buy
8,074
+915
+13% +$28.2K ﹤0.01% 2778
2017
Q1 		$208K Buy
7,159
+135
+2% +$4.11K ﹤0.01% 2912
2016
Q4 		$231K Buy
7,024
+424
+6% +$12.7K ﹤0.01% 2806
2016
Q3 		$208K Sell
6,600
-1,856
-22% -$53.9K ﹤0.01% 2828
2016
Q2 		$238K Buy
8,456
+36
+0.4% +$1.41K ﹤0.01% 2547
2016
Q1 		$306K Buy
+8,420
New +$297K ﹤0.01% 2313

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Raymond James & Associates's EBS Position: Q3 2022 in Review

Raymond James & Associates sold out of Emergent Biosolutions (EBS) in Q3 2022, closing a stake of 21,538 shares — an estimated $669K sold.

Raymond James & Associates first reported a position in EBS in Q1 2016 and held it in 24 quarters. The position peaked at $2.91M in Q1 2021. 210 funds tracked by Wall St. Rank hold EBS as of Q3 2022.

  • Raymond James & Associates reported no remaining Emergent Biosolutions position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 21,538 Emergent Biosolutions shares in Q3 2022, an estimated $669K.
  • Raymond James & Associates first reported a position in Emergent Biosolutions in Q1 2016 and held it in 24 quarters.
  • Raymond James & Associates's Emergent Biosolutions position peaked at $2.91M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.